Eribulin and Body Mass in Metastatic Breast Cancer: News From the Hardest Front of the Battle

The recent publication of the manuscript entitled “Body mass index and treatment outcomes in metastatic breast cancer patients treated with Eribulin”, which has just appeared in the “Journal of Cellular Physiology”, has newly brought metastatic breast cancer to the attention of our cancer research community.

“The recent achievements in the scientific field have significantly widened the therapeutic options available against cancer. In some cases, which surely include breast cancer, the impact of new drugs on treatment outcomes has been undeniable in both the early and advanced phase of the disease.” says Prof. Antonio Giordano, Director of the Sbarro Health Research Organization, Philadelphia, USA.

For more information see the Newslink site or Science Daily site